Copenhagen-based EvodiaBio raises €6 million to scale fermentation-based flavour technology | EU-Startups

Danish flavour company EvodiaBio has raised €6 million (DKK 45 million) in a new funding round to accelerate growth in existing markets and support their expansion into the asian market.

The round was led by the American investment firm RA Capital Management’s Planetary Health Fund and joined by other new investors Wild Radicals and Francis Family Funds, as well as existing investors EIFO, Ananke Ventures, Newtree Impact, PINC (Paulig), Jarne Elleholm (co-founder and Chairman of the Board), Sotirios Kampranis (co-founder), Camilla Kloss Fenneberg (CEO), and three board members: Flemming Besenbacher, Anne Cabotin, and Andreas Fibig.

Today’s funding announcement, follows last year’s €7 million raise – as reported by EU-Startups.

“I am proud of our team – within just three and a half years, we have gone from a research project to industrial production with all necessary approvals and a profitable product. That is rarely seen in the BioTech industry. This investment enables us to accelerate global growth and realise our ambition of becoming a leader in industrial BioTech, says Camilla Fenneberg, CEO of EvodiaBio.

In 2025, EU-Startups reporting points to continued investor interest in fermentation-based and sustainable BioTech, providing a useful context for EvodiaBio’s new round.

French startup Fungu’it raised €4 million to develop natural flavourings using fungi fermentation, underlining demand for alternative aroma and taste solutions with lower environmental impact. In an adjacent application area, Swedish precision-fermentation company Melt&Marble secured €7.3 million to scale its designer fats for food and beauty, while German startup Kynda raised €3 million to expand sustainable fungal protein production.

Taken together, these 2025 rounds amount to approximately €14.3 million invested across flavour, ingredient and fermentation-driven BioTech in Europe.

Against this backdrop, EvodiaBio’s €6 million raise positions it within a broader, data-supported trend of capital flowing into industrial BioTech platforms that apply fermentation to food and beverage value chains, with its specific focus on yeast-derived natural aromas complementing adjacent developments in flavours, fats and proteins.

“RA Capital’s investment in EvodiaBio at this stage underscores the company’s strong position. It confirms that we have removed the key risks related to technology, production, and commercialisation. We have proven that the technology works, that customers are interested in the product, and that the business model has been profitable from day one. Now we are ready to accelerate growth, says Jarne Elleholm, Chairman of the Board at EvodiaBio.

He adds:”What EvodiaBio has achieved in record time is highly unusual in our industry. Moving from the laboratory to a complete production platform, global partnerships, and market interest in such a short time demonstrates that Denmark has the potential to become a leading hub for biosolutions. The new capital allows us to accelerate even further and show how far industrial BioTech can take Denmark.”

Founded in 2021, EvodiaBio is an industrial BioTech company that develops sustainable aromas through fermentation. The technology is used commercially in the beverage industry and enables the production of natural aromas with significantly lower resource consumption and CO₂ emissions than traditional methods.

In just over three years, EvodiaBio has moved from the laboratory to industrial production of yeast-derived natural monoterpenes.

Since the launch of its Yops technology platform earlier this year, EvodiaBio has achieved global commercial traction with more than 70 commercial brews and over 10 projects with top-40 breweries worldwide.

“EvodiaBio’s technology platform convincingly solves the problem of efficiently and sustainably producing natural aromas at industrial scale. The team has executed with a speed and capital efficiency rarely seen in BioTech,” says Kyle Teamey, Managing Partner at RA Capital.

Teamey adds: “We see great potential in the company’s channel partnerships with Symrise and Lallemand and we are excited to support the company as it scales internationally and expands into new segments.”

With its latest investment and strong partnerships, EvodiaBio is well positioned to accelerate its growth. The next steps include expansion into new markets such as Asia and applying its sustainable technology across additional industries, including other beverages, wine, and the aroma industry more broadly.

This latest funding round is the company’s third in three years. In total, EvodiaBio has raised €20 million (DKK 150 million).

“This investment places us in a strong position to accelerate our growth and expand our technology into new markets, especially in Asia. We have achieved strong commercial validation, but we are still early in our growth journey. Our goal is to become a global leader in industrial biotech, and we see a tremendous opportunity to enter multiple industries with our sustainable and efficient solutions,” adds Fenneberg.